Matinas BioPharma Holdings logo

Matinas BioPharma HoldingsNYSE American: MTNB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 July 2014

Next earnings report:

27 March 2025

Last dividends:

N/A

Next dividends:

N/A
$2.94 M
-98%vs. 3y high
8%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:49:13 GMT
$0.58-$0.01(-2.21%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

MTNB Latest News

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
globenewswire.com14 August 2024 Sentiment: POSITIVE

Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Seeking Alpha28 March 2024 Sentiment: NEUTRAL

Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript
Seeking Alpha08 November 2023 Sentiment: POSITIVE

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Penny Stocks To Buy Now? 3 to Watch With Big News
PennyStocks07 November 2023 Sentiment: POSITIVE

Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.

Matinas BioPharma to Present at Two Investment Conferences in October 2023
GlobeNewsWire28 September 2023 Sentiment: POSITIVE

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research10 May 2023 Sentiment: NEUTRAL

Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
GlobeNewsWire03 May 2023 Sentiment: POSITIVE

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

What type of business is Matinas BioPharma Holdings?

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

What sector is Matinas BioPharma Holdings in?

Matinas BioPharma Holdings is in the Healthcare sector

What industry is Matinas BioPharma Holdings in?

Matinas BioPharma Holdings is in the Biotechnology industry

What country is Matinas BioPharma Holdings from?

Matinas BioPharma Holdings is headquartered in United States

When did Matinas BioPharma Holdings go public?

Matinas BioPharma Holdings initial public offering (IPO) was on 21 July 2014

What is Matinas BioPharma Holdings website?

https://www.matinasbiopharma.com

Is Matinas BioPharma Holdings in the S&P 500?

No, Matinas BioPharma Holdings is not included in the S&P 500 index

Is Matinas BioPharma Holdings in the NASDAQ 100?

No, Matinas BioPharma Holdings is not included in the NASDAQ 100 index

Is Matinas BioPharma Holdings in the Dow Jones?

No, Matinas BioPharma Holdings is not included in the Dow Jones index

When was Matinas BioPharma Holdings the previous earnings report?

No data

When does Matinas BioPharma Holdings earnings report?

The next expected earnings date for Matinas BioPharma Holdings is 27 March 2025